аЯрЁБс>ўџ 57ўџџџ4џџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџьЅС'`јПпbjbjыШыШ . ‰Ђ‰Ђп џџџџџџЄъъъъъъъўЦ Ц Ц Ц т ў|ь :< < < < < < < ћ§§§§§§$hhаz!ъЗ < < З З !ъъ< < 6wwwЗ 6ъ< ъ< ћwЗ ћwwъъw< і Т3OЪЦ эRwчL0|wJ?"JwJъwp< Z– @wж 4 ­< < < !!a< < < |З З З З ўўўDB „ўўўB ўўўъъъъъъџџџџ  Manuscript No: 09-LET-129R Author(s): Marcel Leppщe, Mirela Eric and Josip Culig Marcel Leppщe,  HYPERLINK "mailto:marcel.leppee@stampar.hr" marcel.leppee@stampar.hr, Department of Pharmacoepidemiology, Andrija Stampar Institute of Public Health, Mirogojska 16, 10000 Zagreb, Croatia, phone: +38514696166, fax: +38514678013 Mirela Eric,  HYPERLINK "mailto:mirela.eric@gmail.com" mirela.eric@gmail.com, Department of Anatomy, School of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21000 Novi Sad, Serbia, phone: +381638487086 Josip Culig,  HYPERLINK "mailto:josip.culig@stampar.hr" josip.culig@stampar.hr, Department of Pharmacoepidemiology, Andrija Stampar Institute of Public Health, Mirogojska 16, 10000 Zagreb, Croatia, phone: +38514696150, fax: +38514678013 Title: Oral contraceptives containing drospirenone and possible venous thromboembolism Running title: Drospirenone and possible venous thromboembolism Corrected version of the Letter to the Editor Following the publications of papers regarding the risk of VTE with COCs and subsequent criticisms1 (Dinger JFPRHC 2009) we would like to share some information regarding prescribing in Zagreb of a recently introduced COC, containing 3mg drospirenone and 30mcg ethinylestradiol (DRSP/EE) (preparation whose commercial name is Yasmin). We collected data in the city of Zagreb during the 2004-2008 period, employing various data sources: data on inpatients from Zagreb, data on the causes of mortality, data on side effects from the Agency for Drugs and Medicinal Products and data on drug utilization from the Zagreb pharmacies. The total female population under surveillance was about 420,000. In Zagreb, the utilization of oral contraceptives in general increased by 31% between 2004 and 2008. This rising tendency was especially pronounced after 2005 when the combination DRSP/EE was introduced. In 2005, DRSP/EE accounted for 15.4% of overall utilization of oral contraceptives, which increased to 57.7% in 2008, yielding a 4.4-fold increase. Other oral contraceptives classified as fixed combinations of progestogens and estrogens showed a decrease in this period. Like other oral contraceptives, in Zagreb DRSP/EE is issued on private prescription in pharmacies. Oral contraceptives are usually prescribed by gynecologists, but may also be prescribed by other specialists. The number of reported side effects of all drugs of any kind increased by 69.2%, i.e. from 993 in 2005 to 1680 in 2008. Annual trends in the rate of hospitalization showed a decline in women of all age groups as well as in those at a potential exposure to oral contraceptives. Data on the significant increase in the utilization of DRSP/EE and concurrently very low rates of hospitalization for venous thromboembolism, which continue to decline, suggest that there is no correlation between these two parameters. Reference 1. Dinger J Oral contraceptives and venous thromboembolism: old questions revisited. J Fam Plann Reprod Health Care 2009; 35(4): 211-213 457CRSTcd‘’“ЋЌL W Y Z „ … † › œ є ѕ / 0 [ \ ] s t   k | Ќ ѕъткЯкЯкЯЫФЙФЋЙЂЙФЫФЙФ”ЙЂЙФЫФЙФ†ЙЂЙФѕъ~shrvIh#F,mH sH h#F,mH sH jТhš`*h }йUjчhš`*h }йUhš`*h }й0Jjhš`*h }йUjhš`*h }йU hš`*h }йh }йhš`*h }йmH sH h }йmH sH hфMєmH sH hš`*hфMєmH sH hš`*hІ$еmH sH (STK L ! "   k l Ќ ­ Ў Џ А Б В Г с т ˜™Eѓѓѓѓыыыыыыѓѓууыыыыыыыыыыыыdрgd#F,dрgd }й dр7$8$H$gd }йп§Ќ Б В т D E Ь н с ј   . / 2 ˜™EFwƒ“”HJTVѕъѕъоъгЫъЫУДЈ™ъ‘ъ‘ъ‰ъyъiVGhš`*hš`*mH nH sH tH $hŒIhš`*CJaJmH nH sH tH hЄ9CJaJmH nH sH tH hi]mH sH h+)“mH sH hF>4mH sH h#F,mH sH hаХhš`*B*mH phsH hр6 B*mH phsH hаХh(bB*mH phsH hаХmH sH h(bmH sH hš`*h(bmH sH hš`*hš`*H*mH sH hš`*hš`*mH sH hš`*hjАmH sH EFHIJTнопїїыыыпїї dр7$8$H$gd }й dр7$8$H$gd }йdрgd }йVW`ЇЈЉШЮадейкнпєхеШеЖхЄх˜х˜хhš`*hš`*mH sH hи[mH nH sH tH "hи[hš`*5\mH nH sH tH "hš`*hš`*6]mH nH sH tH hи[\mH nH sH tH hš`*hš`*\mH nH sH tH hš`*hš`*mH nH sH tH hЄ9mH nH sH tH ,1hА‚. АЦA!А‰"А‰#‰$‰%ААФАФ ФчDаЩъyљКЮŒ‚ЊKЉ marcel.leppee@stampar.hrрЩъyљКЮŒ‚ЊKЉ @mailto:marcel.leppee@stampar.hrлDаЩъyљКЮŒ‚ЊKЉ mirela.eric@gmail.comрЩъyљКЮŒ‚ЊKЉ :mailto:mirela.eric@gmail.comпDаЩъyљКЮŒ‚ЊKЉ josip.culig@stampar.hrрЩъyљКЮŒ‚ЊKЉ <mailto:josip.culig@stampar.hr†œ@@ёџ@ NormalCJ_HaJmHsHtHDA@ђџЁD Default Paragraph FontRiѓџГR  Table Normalі4ж l4жaі (kєџС(No List6U@Ђё6 фMє Hyperlink >*B*phџ<@< š`* Comment TextCJaJ@j@@ š`*Comment Subject5\B'Ђ!B пComment ReferenceCJaJH™2H п Balloon TextCJOJQJ^JaJп  џџџџSTKL!"klЌ­ЎЏАБВГст˜™E F H I J T н о с ˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€˜0€€SL!"kЌВГст˜H T н о с Š‘00"0YПŠ‘00!€Šб00 Šб00 ЂŠб00 €Šб00€Šб00€ˆ‘00œDПˆ‘00š@0€€Š‘00 јЗРŠ‘00€Š‘00Š‘00Š‘00Š‘00ЬеŠ‘00€š0€€€Š‘00€š0€€Ќ Vп Eп п c’ЋY…›/\sп Xџ„Xџ„Xџ„џџПC0Ќ №РC0ьСC0l|ЫТC0gЭУC0Ь*ФC0„Ў~RЎCCœœс XДIIЂЂс 8*€urn:schemas-microsoft-com:office:smarttags€City€9*€urn:schemas-microsoft-com:office:smarttags€place€ hTЩTc“ЋЎKLW†›žЧЩ!"/]svџ:F[j{‡œЋ&*амчї(.7Cи ч  Ž Ћ Ў Џ Д Е Л с TJL "ntF Н Ћ Ў с 333Љ о с (/с хпр6 ŒIš`*#F,F>4Є9\%<ъ;C“Yи[i](bнf5_ge]Ž+)“jАаХІ$е }йфMєlс Eф66џ@€//x­Щ//п `@џџUnknownџџџџџџџџџџџџGю‡z €џTimes New Roman5€Symbol3&ю ‡z €џArial5&ю ‡za€џTahoma"qˆ№ФЉч‹кЦ ŒкЦХ Х Y№‰‰ДД24й й  2ƒq№HX)№џ?тџџџџџџџџџџџџџџџџџџџџџ\%<ВџџManuscript No: 09-LET-129RMLEPPEEMLEPPEEўџр…ŸђљOhЋ‘+'Гй0„˜МШиф№   @ L Xdlt|тManuscript No: 09-LET-129RMLEPPEE Normal.dotMLEPPEE8Microsoft Office Word@Ј[щ@ђС./OЪ@В*Ї3OЪХ ўџеЭеœ.“—+,љЎDеЭеœ.“—+,љЎl( hp ЈАИ РШаи р т(Zavod za javno zdravstvo grada Zagrebaй ' Manuscript No: 09-LET-129R Title  8@ _PID_HLINKSтAXhmailto:josip.culig@stampar.hr8.Jmailto:mirela.eric@gmail.com8K> mailto:marcel.leppee@stampar.hr8 ўџџџўџџџ !"#ўџџџ%&'()*+ўџџџ-./0123ўџџџ§џџџ6ўџџџўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџ РFЛ Т3OЪ8€Data џџџџџџџџџџџџ1TableџџџџJWordDocumentџџџџ. SummaryInformation(џџџџџџџџџџџџ$DocumentSummaryInformation8џџџџџџџџ,CompObjџџџџџџџџџџџџqџџџџџџџџџџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџ џџџџ РFMicrosoft Office Word Document MSWordDocWord.Document.8є9Вq